To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - TR-1: Standard form for notification of major holdings

Release Date: 26/09/2022 12:00
Code(s): MEI     PDF:  
Wrap Text
TR-1: Standard form for notification of major holdings

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9432434182
(‘Mediclinic’, the ‘Company’, or the ‘Group’)

26 September 2022

TR-1: Standard form for notification of major holdings

1. Issuer Details
   ISIN
   GB00B8HX8Z88
   Issuer Name
   MEDICLINIC INTERNATIONAL PLC
   UK or Non-UK Issuer
   UK

2. Reason for Notification
   An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation
   Name
   JPMorgan Chase & Co.
   City of registered office (if applicable)
   Country of registered office (if applicable)
   US

4. Details of the shareholder
   Name                              City of registered office Country of registered office

   J.P. Morgan Securities plc

5. Date on which the threshold was crossed or reached
   21-Sep-2022

6. Date on which Issuer notified
   23-Sep-2022

7. Total positions of person(s) subject to the notification obligation
                              % of voting        % of voting rights Total of both in   Total number
                              rights attached    through financial  % (8.A + 8.B)      of voting rights
                              to shares (total   instruments                           held in issuer
                              of 8.A)            (total of 8.B 1 +
                                                 8.B 2)

  Resulting                   Below              Below              Below               Below
  situation on the            minimum            minimum            minimum             minimum
  date on which               threshold          threshold          threshold           threshold
  threshold was
  crossed or
  reached

  Position of                 3.444147           1.680406           5.124553
  previous
  notification (if
  applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of          Number of direct Number of indirect       % of direct      % of indirect
shares ISIN            voting rights    voting rights            voting rights    voting rights
code(if possible)      (DTR5.1)         (DTR5.2.1)               (DTR5.1)         (DTR5.2.1)

GB00B8HX8Z88                            Below minimum                             Below
                                        threshold                                 minimum
                                                                                  threshold
Sub Total 8.A
                       Below minimum threshold                   Below minimum
                                                                 threshold

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial     Expiration Exercise/conversion       Number of voting rights that       % of
instrument            date       period                    may be acquired if the             voting
                                                           instrument is                      rights
                                                           exercised/converted
Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
Type of          Expiration     Exercise/conversion Physical or cash     Number of        % of voting
financial        date           period              settlement           voting rights    rights
instrument

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held starting with the
ultimate controlling natural person or legal entities (please add
additional rows as necessary)
Ultimate           Name of controlled   % of voting       % of voting rights    Total of both if
controlling person undertaking          rights if it      through financial     it equals or is
                                        equals or is      instruments if it     higher than
                                        higher than the   equals or is higher   the notifiable
                                        notifiable        than the notifiable   threshold
                                        threshold         threshold

JPMorgan          J.P. Morgan
Chase & Co.       Securities plc

JPMorgan          JPMorgan
Chase & Co.       Chase Bank,
                  National
                  Association

JPMorgan          J.P. Morgan
Chase & Co.       Equities South
                  Africa
                  Proprietary
                  Limited

JPMorgan          J.P. Morgan
Chase & Co.       Securities LLC

10. In case of proxy voting
    Name of the proxy holder
    The number and % of voting rights held
    The date until which the voting rights will be held

11. Additional Information
    Chain of controlled undertakings:

    JPMorgan Chase & Co.
    JPMorgan Chase Bank, National Association (100%)
    J.P. Morgan International Finance Limited (100%)
    J.P. Morgan Capital Holdings Limited (100%)
    J.P. Morgan Securities plc (100%)

    JPMorgan Chase & Co.
    JPMorgan Chase Bank, National Association (100%)

    JPMorgan Chase & Co.
    JPMorgan Chase Bank, National Association (100%)
    J.P. Morgan International Finance Limited (100%)
    J.P. Morgan Capital Holdings Limited (100%)
    J.P. Morgan Equities South Africa Proprietary Limited (100%)

    JPMorgan Chase & Co.
    JPMorgan Chase Holdings LLC (100%)
    J.P. Morgan Broker-Dealer Holdings Inc. (100%)
    J.P. Morgan Securities LLC (100%)

12. Date of Completion
    23-Sep-2022

13. Place Of Completion
    London

About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of
its markets.

At 30 June 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities,
20 day case clinics and 23 outpatient clinics. The Swiss operations included 17 hospitals and four day
case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals (three
of which in Namibia), five subacute hospitals, two mental health facilities and 14 day case clinics (four
of which operated by Intercare) across South Africa, and around 8 650 inpatient beds; and the Middle
East operated seven hospitals, two day case clinics and 23 outpatient clinics with around 1 000 inpatient
beds in the UAE. In addition, under management contract the Middle East will open a 200-bed hospital
in the Kingdom of Saudi Arabia in 2023.

The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United Kingdom, with
secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.7% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930

Investor Relations
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Ben Atwell/Ciara Martin – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment
Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

Date: 26-09-2022 12:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.